News
NBRV
0.1998
-1.82%
-0.0037
BRIEF-Nabriva Therapeutics Reports First Quarter 2022 Financial Results
reuters.com · 05/05 22:18
Nabriva Therapeutics Q1 EPS $(0.20) Misses $(0.19) Estimate, Sales $8.00M Miss $9.57M Estimate
Nabriva Therapeutics (NASDAQ:NBRV) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 62.26 percent increase over losses of $(0.53) per share
Benzinga · 05/05 20:52
Nabriva Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $8.02M misses by $1.55M
Nabriva Therapeutics press release (NASDAQ:NBRV): Q1 GAAP EPS of -$0.20 misses by $0.01. Revenue of $8.02M (+218.3% Y/Y) misses by $1.55M.
Seekingalpha · 05/05 20:33
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
-SIVEXTRO Distribution and Promotion Agreement with Merck Formally Extended Through at Least 2026- -SIVEXTRO Prescription Demand Grew 10% Versus Q1 2021- -Phase 1 XENLETA Cystic Fibrosis Trial Enrollment Progressing- -Conference Call Today at 4:30 p.m. Eas...
GlobeNewswire · 05/05 20:01
-- Earnings Flash (NBRV) NABRIVA THERAPEUTICS US Posts Q1 Loss $-0.20, vs. Street Est of $-0.19
MT Newswires · 05/05 16:36
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/05 12:43
Nabriva extends exclusive contract to sell Merck's antibacterial drug Sivextro in US
Ireland's Nabriva Therapeutics (NASDAQ:NBRV) said it extend its exclusive agreement with Merck (MRK) to promote and distribute the Kenilworth, N.J.-based company's antibacterial drug Sivextro in the U.S. till Dec. 31, 2026. Sivextro
Seekingalpha · 05/05 12:23
BRIEF-Nabriva Extends Exclusive Agreement To Promote And Distribute Sivextro (Tedizolid Phosphate) In The U.S. Through The End Of 2026
reuters.com · 05/05 12:22
Nabriva Therapeutics Reports Extension Of Its Exclusive Deal To Promote, Distribute SIVEXTRO In US Through End Of 2026, No Terms Disclosed
Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it agreed to an
Benzinga · 05/05 11:19
Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections...
GlobeNewswire · 05/05 11:01
Nabriva Therapeutics Q1 2022 Earnings Preview
Nabriva Therapeutics (NASDAQ:NBRV) is scheduled to announce Q1 earnings results on Thursday, May 5th, after market close. The consensus EPS Estimate is -$0.19 (vs. -$0.53 last year) and the consensus Revenue Estimate
Seekingalpha · 05/04 21:35
A Preview Of Nabriva Therapeutics's Earnings
Nabriva Therapeutics (NASDAQ:NBRV) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Nabriva Therapeutics will report an earnings per share (EPS) ...
Benzinga · 05/04 21:18
Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022
DUBLIN, Ireland and FORT WASHINGTON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections...
GlobeNewswire · 05/02 20:05
BRIEF-Nabriva Therapeutics Announces First Patient Enrolled In Phase 1 Trial Of Xenleta In Adult Patients With Cystic Fibrosis
reuters.com · 04/11 20:31
Nabriva Therapeutics Reports First Patient Enrolled In Phase 1 Trial Of XENLETA In Adults With Cystic Fibrosis
Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that the first patient was
Benzinga · 04/11 20:05
Nabriva Therapeutics Announces First Patient Enrolled in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
DUBLIN, Ireland and FORT WASHINGTON, Pa., April 11, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infectio...
GlobeNewswire · 04/11 20:05
Nabriva Therapeutics Enrolls First Patient in Cystic Fibrosis Study
MT Newswires · 04/11 16:40
Northland Securities slashes Nabriva Therapeutics' price target
Investment analysts at Northland Securities have lowered their price target on commercial-stage biopharmaceutical company Nabriva Therapeutics (NBRV -9.1%). In a research note published today, the brokerage slashed NBRV's PT from
Seekingalpha · 03/30 15:12
Nabriva Therapeutics's Return On Capital Employed Overview
Nabriva Therapeutics (NASDAQ:NBRV) brought in sales totaling $9.26 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 22.63%, resulting in a loss of $13.06 million.
Benzinga · 03/30 14:07
--Northland Capital Adjusts Nabriva Therapeutics' Price Target to $2 from $4, Keeps Outperform Rating
MT Newswires · 03/30 12:10
More
Webull provides a variety of real-time NBRV stock news. You can receive the latest news about Nabriva Therapeutics Plc through multiple platforms. This information may help you make smarter investment decisions.
About NBRV
Nabriva Therapeutics plc is a biopharmaceutical company engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company’s product XENLETA (lefamulin), is a semi-synthetic pleuromutilin antibiotic for systematic administration in humans. It inhibits the synthesis of bacterial protein, which is required for bacteria to grow by binding with high affinity, high specificity and at molecular targets that are different than other antibiotic classes. The Company is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.